Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 10 Carcinoma, Hepatocellular 10 Carcinoma, Non-Small-Cell Lung 5 Rectal Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Recurrence 2 Nasopharyngeal Carcinoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Turcot syndrome 1 Thyroid Neoplasms 1 Squamous Non-Small Cell Lung Cancer SqNSCLC 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Resectable Non-small Cell Lung Cancer 1 Rare Tumour 1 Pancreatic Neoplasms 1 Pancreatic Cancer Resectable 1 Pancreatic Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Locally Advanced Non-Small Cell Lung Cancer 1 Hodgkin Disease 1 HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1 Esophageal Neoplasms 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × sintilimab × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡